Takeda Pharmaceutical Company Limited (FRA:TKDA)

Germany flag Germany · Delayed Price · Currency is EUR
13.20
0.00 (0.00%)
At close: Jan 6, 2026
3.94%
Market Cap43.64B
Revenue (ttm)25.44B
Net Income (ttm)190.49M
Shares Outn/a
EPS (ttm)0.12
PE Ratio229.10
Forward PEn/a
Dividend0.50 (3.80%)
Ex-Dividend DateSep 30, 2025
Volumen/a
Average Volume6
Open13.20
Previous Close13.20
Day's Range13.20 - 13.20
52-Week Range11.30 - 14.00
Betan/a
RSI82.89
Earnings DateJan 29, 2026

About FRA:TKDA

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livte... [Read more]

Industry Pharmaceutical Preparations
Founded 1781
Employees 47,455
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol TKDA
Full Company Profile

Financial Performance

In 2024, FRA:TKDA's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.

Financial numbers in JPY Financial Statements

News

There is no news available yet.